Market Cap 3.78B
Revenue (ttm) 398.99M
Net Income (ttm) -257.10M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -64.44%
Debt to Equity Ratio 0.22
Volume 504,000
Avg Vol 708,112
Day's Range N/A - N/A
Shares Out 111.76M
Stochastic %K 73%
Beta 1.08
Analysts Strong Sell
Price Target $56.00

Company Profile

Zai Lab Limited, a biopharmaceutical company, focuses on discovering, developing, and commercializing products that address medical conditions in the areas of oncology, immunology, neuroscience, and infectious diseases. Its commercial products include Zejula, an orally administered poly (ADP-ribose) polymerase 1/2 inhibitor for treating ovarian cancer; VYVGART, a human IgG1 antibody fragment for generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy; NUZYRA for commu...

Industry: Biotechnology
Sector: Healthcare
Phone: 86 21 6163 2588
Address:
Building B, 899 Halei Road, Pudong, China
highnihilism
highnihilism Sep. 30 at 11:04 AM
$TXT Textron: 26 trades, $36K vs $90K avg (0.40x !). $26K calls / $10K puts. $MAC Macerich: 394 trades, $42K vs $84K avg (0.50x !). $26K calls / $17K puts. $ENVA Enova International: 22 trades, $38K vs $23K avg (1.64x). $25K calls / $13K puts. $ZLAB Zai Lab: 37 trades, $26K vs $26K avg (0.99x). $25K calls / $0.3K puts.
0 · Reply
lucgallo
lucgallo Sep. 25 at 1:07 PM
$ZLAB https://ir.zailaboratory.com/news-releases/news-release-details/vertex-announces-key-advancements-across-kidney-portfolio
0 · Reply
Andy_InTheMoney
Andy_InTheMoney Sep. 18 at 8:14 PM
$ZLAB this Chinese name hasn’t moved yet, seems ready with earnings will be double digit growth this year
0 · Reply
Quantumup
Quantumup Sep. 18 at 12:28 PM
Barclays🏁 $ONC Overweight-$385 and said, BeOne (ONC) is a commercial oncology company developing therapies across hematologic and solid tumors. $ONC's broad oncology pipeline positions it for durable growth. Barclay additionally said: We initiate coverage of BeOne (ONC) with an Overweight rating and $385 PT, ahead of two value-inflecting pivotal data readouts; 1) Data for BTK inhibitor in first line mantle cell lymphoma in 2H25; and 2) Data in first line gastroesophageal cancer for PD1 inhibitor + anti-HER2 combination in 4Q25. $ZLAB $PFE $LLY $ABBV
0 · Reply
Mik21212
Mik21212 Sep. 12 at 2:26 PM
$ZLAB up to 34$
0 · Reply
Quantumup
Quantumup Sep. 12 at 9:50 AM
Mizuho reiterated $IDYA Outperform-$44 & said we attended $IDYA's R&D Day earlier this week, with the company featuring presentations on its five highest-priority R&D assets: (1) darovasertib for uveal melanoma/UM; (2) IDE397, a novel MAT2A candidate for MTAP-deleted solid tumors; (3) IDE849, an emerging DLL3-TOP1 ADC candidate; (4) IDE161, a novel PARG inhibitor; and (5) IDE892, a potentially best-in-class PRMT5 inhibitor. Overall, we walked away positively, as we continue to be impressed by $IDYA's ability to execute. On lead asset daro, following the updates we heard (including supportive comments by an uveal melanoma expert), we increase our probability of success/POS assumption to 70% (vs. 60% prior) in the neoadjuvant UM setting, and on other model updates, our PT moves to $44. With the stock down 8% post-the R&D Day event, additional pipeline newsflow expected in the near-term, and model upside from pipeline assets not currently modeled, we stay OP-rated on $IDYA. $AZN $RHHBY $BMY $ZLAB
0 · Reply
Polip
Polip Sep. 12 at 6:26 AM
$ZLAB China stay away from
0 · Reply
Mik21212
Mik21212 Sep. 11 at 7:48 PM
$ZLAB 😎😎😎
0 · Reply
RayRex123
RayRex123 Sep. 11 at 4:26 PM
$ZLAB you mean above $40
1 · Reply
Tdorsey1776
Tdorsey1776 Sep. 11 at 1:34 PM
$ZLAB Needs to get back above $32
0 · Reply
Latest News on ZLAB
Zai Lab's Double Whammy: Earnings Miss, Phase 3 Setback

Sep 11, 2025, 8:02 AM EDT - 23 days ago

Zai Lab's Double Whammy: Earnings Miss, Phase 3 Setback


Zai Lab Establishes Oncology Scientific Advisory Board

Aug 13, 2025, 11:00 AM EDT - 7 weeks ago

Zai Lab Establishes Oncology Scientific Advisory Board


Zai Lab Limited (ZLAB) Q2 2025 Earnings Call Transcript

Aug 7, 2025, 10:29 PM EDT - 2 months ago

Zai Lab Limited (ZLAB) Q2 2025 Earnings Call Transcript


Zai Lab Limited Is Well Positioned For Long-Term Growth

May 28, 2025, 2:48 AM EDT - 4 months ago

Zai Lab Limited Is Well Positioned For Long-Term Growth


Zai Lab Limited: Banking On Chinese Pharma Growth

May 22, 2025, 11:25 AM EDT - 4 months ago

Zai Lab Limited: Banking On Chinese Pharma Growth


Zai Lab Limited (ZLAB) Q1 2025 Earnings Call Transcript

May 11, 2025, 8:55 AM EDT - 5 months ago

Zai Lab Limited (ZLAB) Q1 2025 Earnings Call Transcript


Zai Lab Limited (ZLAB) Q4 2024 Earnings Call Transcript

Feb 27, 2025, 10:46 PM EST - 7 months ago

Zai Lab Limited (ZLAB) Q4 2024 Earnings Call Transcript


Zai Lab: Rapidly Improving Outlook Bodes Well For The Future

Dec 26, 2024, 2:31 PM EST - 10 months ago

Zai Lab: Rapidly Improving Outlook Bodes Well For The Future


Zai Lab Limited (ZLAB) Q3 2024 Earnings Call Transcript

Nov 12, 2024, 11:53 AM EST - 11 months ago

Zai Lab Limited (ZLAB) Q3 2024 Earnings Call Transcript


highnihilism
highnihilism Sep. 30 at 11:04 AM
$TXT Textron: 26 trades, $36K vs $90K avg (0.40x !). $26K calls / $10K puts. $MAC Macerich: 394 trades, $42K vs $84K avg (0.50x !). $26K calls / $17K puts. $ENVA Enova International: 22 trades, $38K vs $23K avg (1.64x). $25K calls / $13K puts. $ZLAB Zai Lab: 37 trades, $26K vs $26K avg (0.99x). $25K calls / $0.3K puts.
0 · Reply
lucgallo
lucgallo Sep. 25 at 1:07 PM
$ZLAB https://ir.zailaboratory.com/news-releases/news-release-details/vertex-announces-key-advancements-across-kidney-portfolio
0 · Reply
Andy_InTheMoney
Andy_InTheMoney Sep. 18 at 8:14 PM
$ZLAB this Chinese name hasn’t moved yet, seems ready with earnings will be double digit growth this year
0 · Reply
Quantumup
Quantumup Sep. 18 at 12:28 PM
Barclays🏁 $ONC Overweight-$385 and said, BeOne (ONC) is a commercial oncology company developing therapies across hematologic and solid tumors. $ONC's broad oncology pipeline positions it for durable growth. Barclay additionally said: We initiate coverage of BeOne (ONC) with an Overweight rating and $385 PT, ahead of two value-inflecting pivotal data readouts; 1) Data for BTK inhibitor in first line mantle cell lymphoma in 2H25; and 2) Data in first line gastroesophageal cancer for PD1 inhibitor + anti-HER2 combination in 4Q25. $ZLAB $PFE $LLY $ABBV
0 · Reply
Mik21212
Mik21212 Sep. 12 at 2:26 PM
$ZLAB up to 34$
0 · Reply
Quantumup
Quantumup Sep. 12 at 9:50 AM
Mizuho reiterated $IDYA Outperform-$44 & said we attended $IDYA's R&D Day earlier this week, with the company featuring presentations on its five highest-priority R&D assets: (1) darovasertib for uveal melanoma/UM; (2) IDE397, a novel MAT2A candidate for MTAP-deleted solid tumors; (3) IDE849, an emerging DLL3-TOP1 ADC candidate; (4) IDE161, a novel PARG inhibitor; and (5) IDE892, a potentially best-in-class PRMT5 inhibitor. Overall, we walked away positively, as we continue to be impressed by $IDYA's ability to execute. On lead asset daro, following the updates we heard (including supportive comments by an uveal melanoma expert), we increase our probability of success/POS assumption to 70% (vs. 60% prior) in the neoadjuvant UM setting, and on other model updates, our PT moves to $44. With the stock down 8% post-the R&D Day event, additional pipeline newsflow expected in the near-term, and model upside from pipeline assets not currently modeled, we stay OP-rated on $IDYA. $AZN $RHHBY $BMY $ZLAB
0 · Reply
Polip
Polip Sep. 12 at 6:26 AM
$ZLAB China stay away from
0 · Reply
Mik21212
Mik21212 Sep. 11 at 7:48 PM
$ZLAB 😎😎😎
0 · Reply
RayRex123
RayRex123 Sep. 11 at 4:26 PM
$ZLAB you mean above $40
1 · Reply
Tdorsey1776
Tdorsey1776 Sep. 11 at 1:34 PM
$ZLAB Needs to get back above $32
0 · Reply
doubleyou2
doubleyou2 Sep. 10 at 9:14 PM
$ZLAB I wish i had more money available at the miment to add here.
0 · Reply
doubleyou2
doubleyou2 Sep. 10 at 8:25 PM
$ZLAB You have cheap. You have very cheap. And you have ZaiLab. Quality company, almost for free. You almost don't find a company with such product pipelines. It is just amazing. If this was a 100% US company, the stockprice would be between $150 and $200. Trump or no Trump...one day this company will be a Big Pharma player.
0 · Reply
Mik21212
Mik21212 Sep. 10 at 5:49 PM
$ZLAB fear creates opportunities😎
0 · Reply
Tdorsey1776
Tdorsey1776 Sep. 10 at 2:51 PM
$ZLAB No impact on ZLAB business other than perception.
1 · Reply
Tdorsey1776
Tdorsey1776 Sep. 10 at 2:22 PM
$ZLAB White House considering banning drugs made in China. https://seekingalpha.com/news/4493678-trump-mulls-crackdown-china-invented-drugs
0 · Reply
Akwaba76
Akwaba76 Sep. 10 at 2:08 PM
$ZLAB is down today, but hey—buying now is like getting a top chef’s tasting menu at half price… just don’t complain if the soufflé takes a while to rise
0 · Reply
SodApOp_PIMPski
SodApOp_PIMPski Sep. 10 at 1:36 PM
$ZLAB bought
1 · Reply
Quantumup
Quantumup Sep. 8 at 10:25 AM
Citizens⬆️ $IDYA's PT to $45 from $41, reiterated at a Market Outperform and said, IDEAYA Biosciences's partner Hengrui showed strong numbers with DLL3-ADC IDE849 (SHR4849) in updated Ph1 data in Chinese patients that cleared the hurdle with more room than anticipated. $AZN $RHHBY $BMY $ZLAB ABBV Citizens added, IDE849 checked all the boxes and showed best-in-class efficacy as well as duration compared to the competitive landscape (details inside). We point to $IDYA's R&D day on Monday morning for more details and we expect the stock to react positively (+10%) on this strong update. We maintain our Market Outperform rating and increase our DCF-derived price target to $45 from $41 based on an increased probability of success (25% from 15%) for IDE849.
0 · Reply
Quantumup
Quantumup Sep. 4 at 12:56 PM
Barclays🏁 $IDYA Overweight/$40. Citizens🏁 $IDYA Market Outperform/$41. $ZLAB $AMGN $DSNKY $PFE GILD AZN RHHBY Barclays and Citizens JMP said in their initiation reports:
0 · Reply
StocktwitsNews
StocktwitsNews Sep. 3 at 3:15 PM
Zai Lab To Await More Trial Data Before Filing For Regulatory Approval For Experimental Cancer Drug $ZLAB $AMGN https://stocktwits.com/news/equity/markets/zai-lab-to-await-more-trial-data-before-filing-for-regulatory-approval-for-experimental-cancer-drug/chwcTXURd8U
0 · Reply
KingThoth509
KingThoth509 Sep. 2 at 12:35 PM
$ZLAB $35 on deck!
0 · Reply
KingThoth509
KingThoth509 Sep. 2 at 12:35 PM
$ZLAB News out ...new drug approval. Should definitely gap up today
0 · Reply